Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug

Clinical Lung Cancer

Volumn 15, Issue 2, 2014, Pages 145-151

  Lee, Youngjoo ^a   Kim, Hyae Young ^a   Lee, Soo Hyun ^a   Lim, Kun Young ^a   Lee, Geon Kook ^a   Yun, Tak ^a   Han, Ji Youn ^a   Kim, Heung Tae ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Acquired resistance; Drug sensitivity; EGFR tyrosine kinase inhibitor; Non small cell lung cancer; Organ

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADENOCARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; FOLLOW UP; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RETREATMENT; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84894025759     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.11.008     Document Type: Article

References (25)

1. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
2. C. Zhou, Y. Wu, and G. Chen et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
3. M. Maemondo, A. Inoue, and K. Kobayashi et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
4. T. Mitsudomi, S. Morita, and Y. Yatabe et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
5. R. Rosell, E. Carcereny, and R. Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
6. K. Park, S. Kim, and D.H. Lee et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 30 2012 1122 1128
7. T.S. Mok, Y. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
8. E. Vasile, C. Tibaldi, and A. Chella et al. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib J Thorac Oncol 3 2008 912 914
9. A. Becker, L. Crombag, and D.A. Heideman et al. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment Eur J Cancer 47 2011 2603 2606
10. Y. Tomizawa, Y. Fujita, and A. Tamura et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy Lung Cancer 68 2010 269 272
11. S.H. Sim, S. Han, and D. Oh et al. Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma Lung Cancer 65 2009 204 207
12. D.B. Costa, K.H. Nguyen, and B.C. Cho et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib Clin Cancer Res 14 2008 7060 7067
13. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
14. D.H. Lee, G.K. Lee, and S. Kong et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma J Clin Pathol 60 2007 881 884
15. J.A. Engelman, K. Zejnullahu, and T. Mitsudomi et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
16. J.M. Wu, M.J. Fackler, and M.K. Halushka et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases Clin Cancer Res 14 2008 1938 1946
17. A.B. Popławski, M. Jankowski, and S.W. Erickson et al. Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression Eur J Hum Genet 18 2010 560 568
18. M. Vecchi, S. Confalonieri, and P. Nuciforo et al. Breast cancer metastases are molecularly distinct from their primary tumors Oncogene 27 2008 2148 2158
19. D.M. Jackman, A.J. Holmes, and N. Lindeman et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib J Clin Oncol 24 2006 4517 4520
20. J.L. Clarke, W. Pao, and N. Wu et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer J Neurooncol 99 2010 283 286
21. C. Grommes, G.R. Oxnard, and M.G. Kris et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer Neuro Oncol 13 2011 1364 1369
22. M.N. Balak, Y. Gong, and G.J. Riely et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin Cancer Res 12 2006 6494 6501
23. S.V. Sharma, D.Y. Lee, and B. Li et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 2010 69 80
24. G.R. Oxnard, Y. Janjigian, and M.E. Arcila et al. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib Clin Cancer Res 17 2011 6322 6328
25. L.V. Sequist, B.A. Waltman, and D. Dias Santagata et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 2011 75ra26